T Cell Redirecting Therapies for Cancer Treatment

Author(s): Barbra Sasu, Javier Chaparro-Riggers

Journal Name: Current Cancer Drug Targets

Volume 16 , Issue 1 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


T cell activity has been stimulated to enhance anti-tumor activity for several decades. Tumor infiltrating lymphocytes have been expanded and reinfused to treat melanoma and other solid tumor cancers, and adaptive immune modulators have been used to increase endogenous T cell activity against cancer. Both of these strategies rely on the pre-existence of adequate recognition of cancer cells by the T cells which are being activated. Redirected T cell therapies represent a paradigm shift in treatment. They do not rely on endogenous T cell recognition but instead focus the T cells onto a defined tumor antigen. This review summarizes both molecular and cellular T cell redirecting therapies, compares their success in the clinic and highlights both their limitations and some potential future solutions.

Keywords: Adoptive immunotherapy, cancer immunotherapy, CAR, CD3 bispecific, chimeric antigen receptor.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 18 December, 2015
Page: [22 - 33]
Pages: 12
DOI: 10.2174/1568009615666150827093149

Article Metrics

PDF: 83
PRC: 1